Silverberg, J. I., Wollenberg, A., Stein Gold, L., Yosipovitch, G., Lio, P.
, Vestergaard, C., Ständer, S., Carrascosa, J. M., Gallo, G., Casillas, M., Ding, Y., Yang, F. E., Pierce, E., Agell, H. & Del Rosso, J. (2026).
Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis.
Clinical and Experimental Dermatology,
51(6), 1012-1019.
https://doi.org/10.1093/ced/llaf490